Document text
Principal Investigator: GREG WITHAM
Organization: ANP TECHNOLOGIES, INC.
Fiscal Year: 2021
Award: $19,727,817
Funding agency: National Heart Lung and Blood Institute
The extreme severity of the current COVID-19 outbreak represents the single worst outbreak in recent years. Exacerbated by the fast moving, highly contagious, asymptomatic disease progression and high mortality in vulnerable populations, particularly those in low resource areas, the need for a rapid, low-cost, easy to use, highly sensitive/clinical relevant, home-use or Point of Care (POC) test to qualitatively detect SARS-nCoV-2 virus is paramount. To combat such a novel virus, it would be highly useful to deploy rapid testing at high frequency using an easy-to-use assay that targets multiple antigens of the virus, yet can return results in only a matter of minutes. The current benchmark of RT-PCR-based testing, although highly sensitive, is only capable of detecting the presence of viral nucleic acids in the patient specimen, unable to provide any information regarding the potential infectiousness of an individual. Moreover, the turnaround time for these tests is abysmal – often taking 3 or more days to get the results and subsequently quarantine these individuals. By then, they have already transmitted the virus to countless others. Currently approved antigen rapid tests, targeting the SARS-CoV-2 nucleocapsid protein, suffer a similar drawback, detecting a single antigen (nucleocapsid). Therefore, an intelligent multiplexed rapid test that can not only detect the nucleocapsid protein antigen, but in addition, distinguish active or potentially highly infectious individuals versus those whom are in the recovery or low state of infectiousness through the added multiplexing of the spike antigen into a single assay is essential to mitigate further infections.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Antigens><Area><Assay><Benchmarking><Best Practice Analysis><Bioassay><Biologic Assays><Biological Assay><COVID-19 antigen><COVID-19 outbreak><COVID-19 virus><COVID19 outbreak><COVID19 virus><CoV emergence><CoV-2><CoV2><Disease Outbreaks><Disease Progression><Frequencies><Home><Individual><Infection><Intelligence><Nanotechnology><Nucleic Acids><Nucleocapsid><Nucleocapsid Proteins><Outbreaks><Patients><Quarantine><RADx Tech><RT-PCR><RTPCR><Rapid Acceleration of Diagnostics Tech><Recovery><Research Resources><Research Specimen><Resources><Reverse Transcriptase Polymerase Chain Reaction><SARS><SARS corona virus 2><SARS coronavirus disease><SARS-CoV disease><SARS-CoV-2><SARS-CoV-2 antigen><SARS-CoV-2 outbreak><SARS-CoV2><SARS-CoV2 antigen><SARS-CoV2 outbreak><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome related corona virus 2><Severities><Specimen><Testing><Time><Viral><Viral Antigens><Virus><Vulnerable Populations><Wuhan coronavirus><base><clinical relevance><clinically relevant><combat><corona virus emergence><coronavirus disease 2019 antigen><coronavirus disease 2019 outbreak><coronavirus disease 2019 virus><coronavirus emergence><cost><detection platform><detection system><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><hCoV19><immunogen><isolation/quarantine><manufacturing scale-up><mortality><nCoV><nCoV2><nano tech><nano technology><nano-technological><nanotech><nanotechnological><new CoV><new corona virus><new coronavirus><novel CoV><novel corona virus><novel coronavirus><novel virus><point of care><rapid assay><rapid test><rapid testing><rapid tests><reverse transcriptase PCR><severe acute respiratory syndrome coronavirus 2 antigen><virus antigen><vulnerable group>